Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Comparative Efficacy, Safety, and Tolerability of Rivastigmine 10 and 15 cm^2 Patch in Patients With Alzheimer's Disease (AD) Showing Cognitive Decline

ClinicalTrials.gov ID: NCT00506415

Public ClinicalTrials.gov record NCT00506415. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 22, 2026, 2:23 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A 48-Week, Multicenter, Randomized, Double-Blind, Parallel-Group Evaluation of the Comparative Efficacy, Safety, and Tolerability of Exelon® 10 and 15 cm^2 Patch in Patients With Mild to Moderate Alzheimer's Disease (AD) Showing Functional and Cognitive Decline

Study identification

NCT ID
NCT00506415
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Novartis Pharmaceuticals
Industry
Enrollment
1,584 participants

Conditions and interventions

Interventions

  • Rivastigmine 5 cm^2 Drug
  • Rivastigmine 10 cm^2 Drug
  • Rivastigmine 15 cm^2 Drug
  • Placebo to 15 cm^2 patch Drug
  • Placebo to 10 cm^2 patch Drug

Drug

Eligibility (public fields only)

Age range
50 Years to 85 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
May 31, 2007
Primary completion
Apr 30, 2011
Completion
Apr 30, 2011
Last update posted
Sep 18, 2012

2007 – 2011

United States locations

U.S. sites
65
U.S. states
22
U.S. cities
64
Facility City State ZIP Site status
Novartis investigative site Birmingham Alabama 35294
Novartis investigative site Gilbert Arizona 85234
Novartis investigative site Phoenix Arizona 85004
Novartis investigative site Sun City Arizona 85351
Novartis investigative site Anaheim California 92804
Novartis investigative site Carson California 90746
Novartis investigative site Costa Mesa California 92626
Novartis investigative site Fullerton California 92835
Novartis investigative site La Habra California 90631
Novartis investigative site La Jolla California 92037
Novartis investigative site National City California 91950
Novartis investigative site Redlands California 92374
Novartis investigative site San Francisco California 94115
Novartis investigative site Fort Collins Colorado 80524
Novartis investigative site Longmont Colorado 80501
Novartis investigative site Boca Raton Florida 33431
Novartis investigative site Bradenton Florida 32405
Novartis investigative site Deerfield Beach Florida 33064
Novartis investigative site Delray Beach Florida 33445
Novartis investigative site Fort Lauderdale Florida 33308
Novartis investigative site Gainesville Florida 32610
Novartis investigative site Miami Beach Florida 33140
Novartis investigative site Pompano Beach Florida 33060
Novartis investigative site Port Charlotte Florida 33952
Novartis investigative site Sunrise Florida 33351
Novartis investigative site West Palm Beach Florida 33407
Novartis investigative site Atlanta Georgia 30341-4155
Novartis investigative site Macon Georgia 31201
Novartis Investigative Site Honolulu Hawaii 96817
Novartis investigative site Chicago Illinois 60611
Novartis investigative site Springfield Massachusetts 01104
Novartis investigative site Flint Michigan 48532
Novartis investigative site Flushing Michigan 48433
Novartis investigative site Roseville Michigan 48066
Novartis investigative site Traverse City Michigan 49684-2340
Novartis investigative site Hattiesburg Mississippi 39401
Novartis investigative site Ocean Springs Mississippi 39564
Novartis investigative site Columbia Missouri 65201
Novartis investigative site St Louis Missouri 63141
Novartis investigative site Flemington New Jersey 08822
Novartis investigative site Nutley New Jersey 07110
Novartis investigative site Somerset New Jersey 08873
Novartis investigative site Albany New York 12208
Novartis investigative site Syracuse New York 13210-1853
Novartis investigative site Greensboro North Carolina 27401
Novartis investigative site Morganton North Carolina 28655
Novartis investigative site Winston-Salem North Carolina 27103-4019
Novartis investigative site Winston-Salem North Carolina 27103
Novartis investigative site Canton Ohio 44718
Novartis investigative site Columbus Ohio 43220
Novartis investigative site Corvallis Oregon 97330
Novartis investigative site Portland Oregon 97225
Novartis investigative site Beaver Pennsylvania 15009-1957
Novartis investigative site Erie Pennsylvania 16506
Novartis investigative site Greensburg Pennsylvania 15601
Novartis investigative site Pittsburgh Pennsylvania 15243
Novartis investigative site Beaufort South Carolina 29902
Novartis investigative site Summerville South Carolina 29485
Novartis investigative site Brentwood Tennessee 37027-5240
Novartis investigative site Nashville Tennessee 37203
Novartis investigative site Dallas Texas 75231
Novartis investigative site Fort Worth Texas 76107
Novartis investigative site Irving Texas 75062
Novartis investigative site Charleston West Virginia 25304
Novartis investigative site Huntington West Virginia 25701

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 79 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00506415, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Sep 18, 2012 · Synced Jul 22, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00506415 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →